Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
PubMed 30097390 ↗Atomoxetine
Also known as Strattera
The short answer. Most people who report on Atomoxetine say it did not help (only 34% of 79 positive). It is most often used for focus: 71% of 45 reports say that improved. It is well studied — 152 meta-analyses on PubMed. The most common complaint is fatigue.
From 137 mentions in total — the rest didn't say how it went and aren't counted.
What Atomoxetine does, according to users
Of the people who reported each effect, the share who said it got better.
3 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 152 meta-analyses on PubMed ↗ · 268 randomized trials ↗
Conclusion: In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and nonstimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and nonpharmacological interventions is likely to further improve QoL in people with ADHD.
PubMed 38823477 ↗Conclusion: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
PubMed 35246237 ↗Conclusion: Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings. However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated. The effects of non-pharmacological strategies were inconsistent across different raters. Our network meta-analysis represents the most comprehensive synthesis of available evide
PubMed 39701638 ↗224 human trials on ClinicalTrials.gov test Atomoxetine — 170 completed, 14 recruiting now. See all on ClinicalTrials.gov ↗
- Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) · OSA · 2025
- Parallel Arm Trial of AD109 and AD504 In Patients With OSA · OSA - Obstructive Sleep Apnea · 2022
- A Novel Pharmacological Therapy for Obstructive Sleep Apnea · Sleep Apnea · 2023
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All atomoxetine-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the…”
19 recalls of products named for Atomoxetine. Most recent:
- 2026-05-27 · Class II: Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule. record ↗
- 2025-02-26 · Class II: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. record ↗
- 2015-04-29 · Class II: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
26,969 adverse-event reports mention Atomoxetine. Most often reported:
- Drug ineffective · 2,955
- Nausea · 2,250
- Fatigue · 2,244
- Headache · 1,844
- Vomiting · 1,814
- Off label use · 1,799
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Atomoxetine C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗
NIH has funded 19 research projects with Atomoxetine in the title, $11,853,723 in total (2004–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Atomoxetine ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“Helps focus / concentration immensely... Seems to improve my memory as well.”
“Atomoxetine made me way more impulsive and gave me sexual side effects right off the bat.”
“Currently I am on Strattera and the side effects have subsided so I am only feeling the positives. A lot less stress and anxiety and ADHD is minimal.”
“I've tried the traditional ADHD meds like Strattera and Guanfacine, and they don't offer any improvement.”
Top discussions (5)
- Just an FYI: be extremely careful with prescription amphetamines…. The road off them is long and painful. ↗
- Bio hacking for depression ↗
- Did i destroy my dopamine neurons? ↗
- Supplementation guide to stimulants ↗
- (2003) Seligiline treats ADHD with less side effects than Ritalin in double blinded, randomized trial ↗
Other options for focus
Sources
- User reports: 137 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate